Trials / Not Yet Recruiting
Not Yet RecruitingNCT07080671
Clinical and Radiographic Outcomes of the JointMedica Polymotion Resurfacing (PHR) Device
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 105 (estimated)
- Sponsor
- JointMedica Inc. · Academic / Other
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Accepted
Summary
The goal of this observational study is to generate Real World Evidence (RWE) on the device performance of the Polymotion Hip Resurfacing (PHR) system and its use in patients who have been implanted with the device for the treatment of hip osteoarthritis. This study will assess the following endpoints: * The survivorship of the Acetabular Cup (Kaplan-Meier estimate) through 2 years of follow-up. * Radiographic success of the implanted cups, through quantitative motion analysis to assess migration of the acetabular cups. * Absence of subsequent surgical intervention at the acetabulum of there operated hip. * Absence of serious, device-related adverse events. * Patient reported outcomes through Harris Hip Score and SUSHI - UCLA Hip Score questionnaires.
Detailed description
This is a retrospective and prospective study that will include a maximum of 70 patients who were implanted with the JointMedica Polymotion Hip Resurfacing (PHR) device in Canada, New Zealand and Australia. Patients will be invited to consent to participate in this study, which will require their attendance of a follow-up standard of care visit to gather clinical data on the safety and performance of their index hip, undergo an x-ray imaging and complete two questionnaires to assess their functionality and outcomes. Patient data will be entered into electronic data capture systems and x-rays will be submitted to a core imaging laboratory, MMI, for analysis to assess the state and position of their acetabular cup.
Conditions
Timeline
- Start date
- 2025-07-25
- Primary completion
- 2026-10-31
- Completion
- 2026-12-31
- First posted
- 2025-07-23
- Last updated
- 2025-07-23
Locations
3 sites across 3 countries: Australia, Canada, New Zealand
Source: ClinicalTrials.gov record NCT07080671. Inclusion in this directory is not an endorsement.